...
search icon
bpmc-img

Blueprint Medicines Corp, Common Stock

BPMC

NSQ

$114.32

-$0.15

(-0.13%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.16B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
650.38K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.59
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$72.24 L
$121.9 H
$114.32

About Blueprint Medicines Corp, Common Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBPMCSectorS&P500
1-Week Return2.92%3.05%-0.32%
1-Month Return31.67%6.76%2.75%
3-Month Return37.07%-1.27%3.94%
6-Month Return3.61%-2.35%11.01%
1-Year Return34.42%4.47%23.11%
3-Year Return48.27%11.65%34.36%
5-Year Return72.9%43.79%85.19%
10-Year Return505.83%108.21%200.02%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue66.51M793.74M180.08M204.04M249.38M[{"date":"2019-12-31","value":8.38,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22.69,"profit":true},{"date":"2022-12-31","value":25.71,"profit":true},{"date":"2023-12-31","value":31.42,"profit":true}]
Cost of Revenue331.45M425.00K17.93M17.81M12.80M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.13,"profit":true},{"date":"2021-12-31","value":5.41,"profit":true},{"date":"2022-12-31","value":5.37,"profit":true},{"date":"2023-12-31","value":3.86,"profit":true}]
Gross Profit66.51M793.31M162.15M186.22M236.58M[{"date":"2019-12-31","value":8.38,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":20.44,"profit":true},{"date":"2022-12-31","value":23.47,"profit":true},{"date":"2023-12-31","value":29.82,"profit":true}]
Gross Margin100.00%99.95%90.04%91.27%94.87%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.95,"profit":true},{"date":"2021-12-31","value":90.04,"profit":true},{"date":"2022-12-31","value":91.27,"profit":true},{"date":"2023-12-31","value":94.87,"profit":true}]
Operating Expenses427.84M484.60M804.13M723.74M722.86M[{"date":"2019-12-31","value":53.21,"profit":true},{"date":"2020-12-31","value":60.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90,"profit":true},{"date":"2023-12-31","value":89.89,"profit":true}]
Operating Income(366.58M)302.15M(648.46M)(549.25M)(486.28M)[{"date":"2019-12-31","value":-121.33,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-214.62,"profit":false},{"date":"2022-12-31","value":-181.78,"profit":false},{"date":"2023-12-31","value":-160.94,"profit":false}]
Total Non-Operating Income/Expense32.62M12.83M3.28M(31.53M)(42.60M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.33,"profit":true},{"date":"2021-12-31","value":10.06,"profit":true},{"date":"2022-12-31","value":-96.65,"profit":false},{"date":"2023-12-31","value":-130.59,"profit":false}]
Pre-Tax Income(347.69M)314.94M(641.08M)(552.28M)(506.02M)[{"date":"2019-12-31","value":-110.4,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-203.56,"profit":false},{"date":"2022-12-31","value":-175.36,"profit":false},{"date":"2023-12-31","value":-160.67,"profit":false}]
Income Taxes(18.99M)1.06M3.00M5.24M968.00K[{"date":"2019-12-31","value":-362.7,"profit":false},{"date":"2020-12-31","value":20.21,"profit":true},{"date":"2021-12-31","value":57.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":18.49,"profit":true}]
Income After Taxes(328.70M)313.88M(644.09M)(557.52M)(506.98M)[{"date":"2019-12-31","value":-104.72,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-205.2,"profit":false},{"date":"2022-12-31","value":-177.62,"profit":false},{"date":"2023-12-31","value":-161.52,"profit":false}]
Income From Continuous Operations(414.21M)313.88M(644.09M)(557.52M)(554.71M)[{"date":"2019-12-31","value":-131.96,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-205.2,"profit":false},{"date":"2022-12-31","value":-177.62,"profit":false},{"date":"2023-12-31","value":-176.73,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(328.70M)313.88M(644.09M)(557.52M)(506.98M)[{"date":"2019-12-31","value":-104.72,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-205.2,"profit":false},{"date":"2022-12-31","value":-177.62,"profit":false},{"date":"2023-12-31","value":-161.52,"profit":false}]
EPS (Diluted)(7.30)5.24(10.92)(9.35)(8.36)[{"date":"2019-12-31","value":-139.31,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-208.4,"profit":false},{"date":"2022-12-31","value":-178.44,"profit":false},{"date":"2023-12-31","value":-159.54,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BPMC
Cash Ratio 2.85
Current Ratio 3.32
Quick Ratio 3.27

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BPMC
ROA (LTM) -14.97%
ROE (LTM) -49.66%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BPMC
Debt Ratio Lower is generally better. Negative is bad. 0.74
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.26

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BPMC
Trailing PE NM
Forward PE NM
P/S (TTM) 16.74
P/B 23.10
Price/FCF NM
EV/R 16.05
EV/Ebitda NM
PEG NM

FAQs

What is Blueprint Medicines Corp share price today?

Blueprint Medicines Corp (BPMC) share price today is $114.32

Can Indians buy Blueprint Medicines Corp shares?

Yes, Indians can buy shares of Blueprint Medicines Corp (BPMC) on Vested. To buy Blueprint Medicines Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BPMC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Blueprint Medicines Corp be purchased?

Yes, you can purchase fractional shares of Blueprint Medicines Corp (BPMC) via the Vested app. You can start investing in Blueprint Medicines Corp (BPMC) with a minimum investment of $1.

How to invest in Blueprint Medicines Corp shares from India?

You can invest in shares of Blueprint Medicines Corp (BPMC) via Vested in three simple steps:

  • Click on Sign Up or Invest in BPMC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Blueprint Medicines Corp shares
What is Blueprint Medicines Corp 52-week high and low stock price?

The 52-week high price of Blueprint Medicines Corp (BPMC) is $121.9. The 52-week low price of Blueprint Medicines Corp (BPMC) is $72.24.

What is Blueprint Medicines Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Blueprint Medicines Corp (BPMC) is 23.10

What is the Market Cap of Blueprint Medicines Corp?

The market capitalization of Blueprint Medicines Corp (BPMC) is $7.16B

What is Blueprint Medicines Corp’s stock symbol?

The stock symbol (or ticker) of Blueprint Medicines Corp is BPMC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top